BRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations

Reuters10-22

Oct 22 (Reuters) - Indaptus Therapeutics Inc :

* INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS

* INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED TO START IN 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477228336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477228336","market":"us","top_or_hot":-1,"title":"BRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations","media":"Reuters","content":"<html><body><p>Oct 22 (Reuters) - Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS</p><p>   * INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED  TO START IN 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-22 20:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 22 (Reuters) - Indaptus Therapeutics Inc   :   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS   * INDAPTUS THERAPEUTICS ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2477228336","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477228336","pubTimestamp":1729600830,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 22  - Indaptus Therapeutics Inc   :   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS   * INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED  TO START IN 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BGNE":"百济神州","BK4139":"生物科技","INDP":"Indaptus Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"简介-Indaptus Therapeutics宣布与百济神州达成临床供应协议，以评估新型癌症治疗组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1,"LENZ":1,"INDP":0.9},"content_text":"Oct 22 (Reuters) - Indaptus Therapeutics Inc   :   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS   * INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED  TO START IN 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477228336"}